Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

William Henderson

Pulmonary Disease Danville, VA Medical Doctor

NPI 1497755680 CMS profile 248997

159 Executive Dr, Suite F, Danville, VA 24541

Open in the dashboard

General payments

$4,949

270 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, William Henderson of Danville, VA is reported in the CMS Open Payments database as having received $4,949 across 270 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 67th percentile of Pulmonary Disease profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $14 1
2024 General $16 1
2023 General $14 1
2022 General $970 49
2021 General $1,345 88
2020 General $927 52
2019 General $1,662 78

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • William Henderson
  • Pulmonary Disease median
  • Middle half of Pulmonary Disease
  • National median

In program year 2025, general payments to William Henderson were reported at $14. Among 8,914 Pulmonary Disease profiles paid that year, the median was $500 and the middle half received between $124 and $1,893.

Show as a table
Year William Henderson Pulmonary Disease median Middle half National median
2019 $1,662 $377 $109–$1,340 $163
2020 $927 $230 $56–$907 $114
2021 $1,345 $269 $68–$1,072 $132
2022 $970 $390 $100–$1,457 $149
2023 $14 $419 $114–$1,659 $160
2024 $16 $476 $123–$1,818 $164
2025 $14 $500 $124–$1,893 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AstraZeneca Pharmaceuticals LP $1,155 43 payments
  2. GlaxoSmithKline, LLC. $1,084 86 payments
  3. Genzyme Corporation $301 13 payments
  4. Genentech USA, Inc. $298 10 payments
  5. Actelion Pharmaceuticals US, Inc. $265 9 payments
  6. Philips Electronics North America Corporation $232 12 payments
  7. Sunovion Pharmaceuticals Inc. $213 12 payments
  8. Boehringer Ingelheim Pharmaceuticals, Inc. $212 11 payments
  9. Mylan Specialty L.P. $190 14 payments
  10. Mallinckrodt Enterprises LLC $132 9 payments
  11. Other $869 51 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $4,879 267 payments
  2. Education $70 3 payments
Products named General payments · program years 2019–2025
  1. TRELEGY ELLIPTA $540 53 payments
  2. FASENRA Respiratory $447 11 payments
  3. DUPIXENT $327 14 payments
  4. NUCALA $314 16 payments
  5. FASENRA Respiratory $302 13 payments
  6. FARXIGA $300 4 payments
  7. Xolair $298 10 payments
  8. UPTRAVI $265 9 payments
  9. LONHALA MAGNAIR $213 12 payments
  10. BREZTRI $175 2 payments
  11. Other $2,498 142 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

270 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pulmonary Disease in Virginia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record